
Michael Linnebacher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1463106/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. Cell Biology and Toxicology, 2023, 39, 2401-2419.	5.3	6
2	The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner. Molecular Cancer Therapeutics, 2022, 21, 100-112.	4.1	9
3	Glucose Influences the Response of <i>Glioblastoma</i> Cells to Temozolomide and Dexamethasone. Cancer Control, 2022, 29, 107327482210754.	1.8	3
4	Microsatellite Status and lκBα Expression Levels Predict Sensitivity to Pharmaceutical Curcumin in Colorectal Cancer Cells. Cancers, 2022, 14, 1032.	3.7	4
5	Galvanotactic Migration of Glioblastoma and Brain Metastases Cells. Life, 2022, 12, 580.	2.4	6
6	Global Association of Cause-specific Mortality between the Major Gastrointestinal Cancers and Parkinson's Disease for the First Two Decades of the New Millennium. , 2022, 13, 534.		0
7	A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer. Cancers, 2022, 14, 3252.	3.7	1
8	Global metabolic alterations in colorectal cancer cells during irinotecan-induced DNA replication stress. Cancer & Metabolism, 2022, 10, .	5.0	8
9	Correlation between Kir4.1 expression and barium-sensitive currents in rat and human glioma cell lines. Neuroscience Letters, 2021, 741, 135481.	2.1	5
10	Analyzing non ancer causes of death of colorectal carcinoma patients in the US population for the years 2000–2016. Cancer Medicine, 2021, 10, 2740-2751.	2.8	9
11	CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens. Molecular and Cellular Proteomics, 2021, 20, 100032.	3.8	22
12	Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells. British Journal of Cancer, 2021, 124, 1411-1420.	6.4	8
13	Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: an updated population-based study. Future Oncology, 2021, 17, 549-563.	2.4	8
14	Creation and Maintenance of a Living Biobank - How We Do It. Journal of Visualized Experiments, 2021, ,	0.3	4
15	Combined Targeting of AKT and mTOR Synergistically Inhibits Formation of Primary Colorectal Carcinoma Tumouroids <i>In Vitro</i> : A 3D Tumour Model for Pre-therapeutic Drug Screening. Anticancer Research, 2021, 41, 2257-2275.	1.1	8
16	Mechanistic insights into p53â€regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells. Molecular Oncology, 2021, 15, 3404-3429.	4.6	15
17	Tumour-Derived Cell Lines and Their Potential for Therapy Prediction in Patients with Metastatic Colorectal Cancer. Cancers, 2021, 13, 4717.	3.7	6
18	A global assessment of recent trends in gastrointestinal cancer and lifestyleâ€associated risk factors. Cancer Communications, 2021, 41, 1137-1151.	9.2	85

#	Article	IF	CITATIONS
19	Cancer-Cell-Derived IgG and Its Potential Role in Tumor Development. International Journal of Molecular Sciences, 2021, 22, 11597.	4.1	25
20	The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models. Cancers, 2021, 13, 5882.	3.7	5
21	NSG mice as hosts for oncological precision medicine. Laboratory Investigation, 2020, 100, 27-37.	3.7	26
22	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research, 2020, 26, 1372-1384.	7.0	66
23	Connecting Cancer Pathways to Tumor Engines: A Stratification Tool for Colorectal Cancer Combining Human In Vitro Tissue Models with Boolean In Silico Models. Cancers, 2020, 12, 28.	3.7	14
24	Patient-individual cancer cell lines and tissue analysis delivers no evidence of sequences from DNA viruses in colorectal cancer cells. BMC Gastroenterology, 2020, 20, 260.	2.0	2
25	Mouse models of colorectal cancer: Past, present and future perspectives. World Journal of Gastroenterology, 2020, 26, 1394-1426.	3.3	89
26	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clinical Cancer Research, 2019, 25, 6243-6259.	7.0	42
27	Integrated Biobanking and Tumor Model Establishment of Human Colorectal Carcinoma Provides Excellent Tools for Preclinical Research. Cancers, 2019, 11, 1520.	3.7	31
28	Human Colorectal Carcinoma Infiltrating B Lymphocytes Are Active Secretors of the Immunoglobulin Isotypes A, G, and M. Cancers, 2019, 11, 776.	3.7	11
29	Targeting Immune-Related Molecules in Cancer Therapy: A ComprehensiveIn VitroAnalysis on Patient-Derived Tumor Models. BioMed Research International, 2019, 2019, 1-12.	1.9	9
30	AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro. PLoS ONE, 2019, 14, e0211644.	2.5	56
31	Abstract LB-299: A comprehensive platform of patient-derived xenografts and matched cell lines mirrors the genomic landscape of colorectal cancer. , 2019, , .		0
32	Abstract A014: Gastric cancer PDX models for predictive preclinical studies: Establishment, drug sensitivity, and genomic characterization. , 2019, , .		0
33	β-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells. Scientific Reports, 2018, 8, 3178.	3.3	45
34	Cellular vaccination of MLH1 ^{â^'/â^'} mice – an immunotherapeutic proof of concept study. Oncolmmunology, 2018, 7, e1408748.	4.6	13
35	Colorectal cancer vaccines: Tumor-associated antigens <i>vs</i> neoantigens. World Journal of Gastroenterology, 2018, 24, 5418-5432.	3.3	77
36	Murine Endogenous Retroviruses Are Detectable in Patient-Derived Xenografts but Not in Patient-Individual Cell Lines of Human Colorectal Cancer. Frontiers in Microbiology, 2018, 9, 789.	3.5	6

#	Article	IF	CITATIONS
37	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. Nature Communications, 2018, 9, 2287.	12.8	18
38	Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in in vitro models of patient individual glioblastoma. PLoS ONE, 2018, 13, e0191511.	2.5	17
39	Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells. Oncotarget, 2018, 9, 27835-27850.	1.8	19
40	Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line. World Journal of Gastroenterology, 2018, 24, 3749-3759.	3.3	11
41	Establishment, functional and genetic characterization of three novel patient-derived rectal cancer cell lines. World Journal of Gastroenterology, 2018, 24, 4880-4892.	3.3	7
42	Abstract 205: Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. , 2018, , .		0
43	Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repairâ€deficiency and Lynch syndrome. Molecular Carcinogenesis, 2017, 56, 1753-1764.	2.7	13
44	Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin. Neoplasia, 2017, 19, 301-309.	5.3	33
45	Deciphering molecular mechanisms of arginine deiminase-based therapy – Comparative response analysis in paired human primary and recurrent glioblastomas. Chemico-Biological Interactions, 2017, 278, 179-188.	4.0	15
46	The HROC Collection and Matching Pairs of Colorectal Cancer Models (PDX and Cell Lines) from Primaries and Metastases. Gastroenterology, 2017, 152, S1279.	1.3	0
47	Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies. Journal of Translational Medicine, 2017, 15, 27.	4.4	41
48	Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells. Cellular Signalling, 2017, 29, 218-225.	3.6	41
49	Generation of Xenotransplants from Human Cancer Biopsies to Assess Anti-cancer Activities of HDACi. Methods in Molecular Biology, 2017, 1510, 217-229.	0.9	11
50	Colorectal carcinoma tumour budding and podia formation in the xenograft microenvironment. PLoS ONE, 2017, 12, e0186271.	2.5	14
51	Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme. PLoS ONE, 2017, 12, e0185208.	2.5	14
52	Application of <i>in vivo</i> imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer. Oncotarget, 2017, 8, 69756-69767.	1.8	10
53	Tumor Take Rate Optimization for Colorectal Carcinoma Patient-Derived Xenograft Models. BioMed Research International, 2016, 2016, 1-7.	1.9	28
54	Generation, Characterization and Application of Antibodies Directed against HERV-H Gag Protein in Colorectal Samples. PLoS ONE, 2016, 11, e0153349.	2.5	12

#	Article	IF	CITATIONS
55	Establishment and characterization of HROC69 – a Crohn´s related colonic carcinoma cell line and its matched patient-derived xenograft. Scientific Reports, 2016, 6, 24671.	3.3	12
56	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i> -Mutant Colorectal Cancer. Cancer Research, 2016, 76, 4504-4515.	0.9	91
57	The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis. Oncotarget, 2016, 7, 53583-53598.	1.8	12
58	Optimizing the process of nucleofection for professional antigen presenting cells. BMC Research Notes, 2015, 8, 472.	1.4	5
59	Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Oncotarget, 2015, 6, 39342-39356.	1.8	20
60	Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes. Oncotarget, 2015, 6, 40095-40111.	1.8	52
61	Arginine deprivation by arginine deiminase ofStreptococcus pyogenescontrols primary glioblastoma growthin vitroandin vivo. Cancer Biology and Therapy, 2015, 16, 1047-1055.	3.4	52
62	Stage-specific frequency and prognostic significance of aneuploidy in patients with sporadic colorectal cancer—a meta-analysis and current overview. International Journal of Colorectal Disease, 2015, 30, 1015-1028.	2.2	15
63	MicroRNA–mRNA interactions in colorectal cancer and their role in tumor progression. Genes Chromosomes and Cancer, 2015, 54, 129-141.	2.8	70
64	Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1927-34.	2.3	10
65	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nature Communications, 2015, 6, 7002.	12.8	251
66	Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype. PLoS ONE, 2015, 10, e0143194.	2.5	12
67	Establishment and characterization of cell lines from chromosomal instable colorectal cancer. World Journal of Gastroenterology, 2015, 21, 164.	3.3	27
68	Reactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease. World Journal of Gastroenterology, 2015, 21, 221.	3.3	1
69	Abstract 2043: SATB1 (special AT-rich binding protein 1) as a putative therapeutic target in colorectal cancer. , 2015, , .		0
70	Abstract B24: Therapeutic response to bevacicumab, irinotecan, and temozolomide of PDX from human glioma cannot be correlated to common mutations as routinely identified by panel sequencing. , 2015, ,		0
71	The impact of pyrvinium pamoate on colon cancer cell viability. International Journal of Colorectal Disease, 2014, 29, 1189-1198.	2.2	29
72	Biological and Molecular Effects of Small Molecule Kinase Inhibitors on Low-Passage Human Colorectal Cancer Cell Lines. BioMed Research International, 2014, 2014, 1-13.	1.9	18

#	Article	IF	CITATIONS
73	E7080 (Lenvatinib), a Multi-Targeted Tyrosine Kinase Inhibitor, Demonstrates Antitumor Activities Against Colorectal Cancer Xenografts. Neoplasia, 2014, 16, 972-981.	5.3	20
74	Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochemical Pharmacology, 2014, 92, 312-325.	4.4	79
75	PTEN mutation, loss of heterozygosity, promoter methylation and expression in colorectal carcinoma: Two hits on the gene?. Oncology Reports, 2014, 31, 2236-2244.	2.6	10
76	Host defense peptides for treatment of colorectal carcinoma - a comparative in vitro and in vivo analysis. Oncotarget, 2014, 5, 4467-4479.	1.8	20
77	Accounting for randomness in measurement and sampling in studying cancer cell population dynamics. IET Systems Biology, 2014, 8, 230-241.	1.5	0
78	Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1425-1431.	2.5	4
79	Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy. Cancer Immunology, Immunotherapy, 2013, 62, 1283-1292.	4.2	19
80	Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies. European Journal of Cancer, 2013, 49, 2587-2595.	2.8	28
81	The "North German Tumor Bank of Colorectal Cancer― status report after the first 2Âyears of support by the German Cancer Aid Foundation. Langenbeck's Archives of Surgery, 2013, 398, 251-258.	1.9	16
82	Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib. Journal of Lipid Research, 2013, 54, 3116-3129.	4.2	31
83	COX-2 and PPAR-Î ³ Confer Cannabidiol-Induced Apoptosis of Human Lung Cancer Cells. Molecular Cancer Therapeutics, 2013, 12, 69-82.	4.1	169
84	Microsatellite instability in hematological malignancies. OncoImmunology, 2013, 2, e25419.	4.6	4
85	Single nucleotide polymorphism array analysis of microsatellite-stable, diploid/near-diploid colorectal carcinomas without the CpG island methylator phenotype. Oncology Letters, 2013, 5, 173-178.	1.8	8
86	Establishment and Characterization of Primary Glioblastoma Cell Lines from Fresh and Frozen Material: A Detailed Comparison. PLoS ONE, 2013, 8, e71070.	2.5	41
87	Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy. Clinical and Developmental Immunology, 2013, 2013, 1-14.	3.3	26
88	Tumor-infiltrating B cells come into vogue. World Journal of Gastroenterology, 2013, 19, 8.	3.3	17
89	Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells. International Journal of Oncology, 2012, 40, 764-72.	3.3	6
90	Reevaluating the Concept of Treating Experimental Tumors with a Mixed Bacterial Vaccine: Coley's Toxin. Clinical and Developmental Immunology, 2012, 2012, 1-16.	3.3	12

#	Article	IF	CITATIONS
91	Tumor-infiltrating B cells. Oncolmmunology, 2012, 1, 1186-1188.	4.6	58
92	Cannabidiol inhibits lung cancer cell invasion and metastasis <i>via</i> intercellular adhesion moleculeâ€1. FASEB Journal, 2012, 26, 1535-1548.	0.5	138
93	Combining bacterial-immunotherapy with therapeutic antibodies: A novel therapeutic concept. Vaccine, 2012, 30, 2786-2794.	3.8	5
94	Microdensitometry of osteopontin as an immunohistochemical prognostic biomarker in colorectal carcinoma tissue microarrays: potential and limitations of the method in â€~biomarker pathology'. Histopathology, 2012, 61, 823-832.	2.9	3
95	Ex-vivo Clonally Expanded B Lymphocytes Infiltrating Colorectal Carcinoma Are of Mature Immunophenotype and Produce Functional IgG. PLoS ONE, 2012, 7, e32639.	2.5	40
96	Establishment, Characterization and Chemosensitivity of Three Mismatch Repair Deficient Cell Lines from Sporadic and Inherited Colorectal Carcinomas. PLoS ONE, 2012, 7, e52485.	2.5	49
97	Clonality characterization of natural epitope-specific antibodies against the tumor-related antigen topoisomerase IIa by peptide chip and proteome analysis: a pilot study with colorectal carcinoma patient samples. Analytical and Bioanalytical Chemistry, 2012, 403, 227-238.	3.7	20
98	Endogenous retrovirus sequences as a novel class of tumor-specific antigens: an example of HERV-H env encoding strong CTL epitopes. Cancer Immunology, Immunotherapy, 2012, 61, 1093-1100.	4.2	55
99	Bacterial immunotherapy of gastrointestinal tumors. Langenbeck's Archives of Surgery, 2012, 397, 557-568.	1.9	26
100	Human endogenous retroviruses and cancer: Causality and therapeutic possibilities. World Journal of Gastroenterology, 2012, 18, 6027.	3.3	27
101	Gene Chip Analysis for Detection of Potential Tumor Suppressor Genes in Colorectal Cancer Cell Lines. Gastroenterology, 2011, 140, S-1042.	1.3	1
102	Impact of portal branch ligation on tissue regeneration, microcirculatory response and microarchitecture in portal blood-deprived and undeprived liver tissue. Microvascular Research, 2011, 81, 274-280.	2.5	25
103	Semiallogenic fusions of MSI+tumor cells and activated B cells induce MSI-specific T cell responses. BMC Cancer, 2011, 11, 410.	2.6	3
104	Avitalized bacteria mediate tumor growth control via activation of innate immunity. Cellular Immunology, 2011, 269, 120-127.	3.0	17
105	Multidrug-resistance proteins are weak tumor associated antigens for colorectal carcinoma. BMC Immunology, 2011, 12, 38.	2.2	7
106	An MSI Tumor Specific Frameshift Mutation in a Coding Microsatellite of MSH3 Encodes for HLA-A0201-Restricted CD8+ Cytotoxic T Cell Epitopes. PLoS ONE, 2011, 6, e26517.	2.5	25
107	Bacteriolytic therapy of experimental pancreatic carcinoma. World Journal of Gastroenterology, 2010, 16, 3546.	3.3	22
108	Generation of highly pure fusions of colorectal carcinoma and antigen-presenting cells. Langenbeck's Archives of Surgery, 2010, 395, 365-371.	1.9	6

#	Article	IF	CITATIONS
109	Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer, 2010, 10, 362.	2.6	72
110	Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. Experimental Hematology, 2010, 38, 1066-1073.	0.4	22
111	Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. International Journal of Cancer, 2010, 127, 889-898.	5.1	46
112	The EpCAM ^{high} /CD44 ^{high} colorectal carcinoma stem cell phenotype is not preferentially expressed in tumour buds. Histopathology, 2010, 56, 553-555.	2.9	6
113	Identification of an MSI-H Tumor-Specific Cytotoxic T Cell Epitope Generated by the (<mml:math) 0.78<br="" 1="" etqq1="" tj="">Frame of<i>U79260(FTO)</i>. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.</mml:math)>	34314 rgB 3.0	T /Overlock 29
114	Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. International Journal of Oncology, 2009, 35, 321-7.	3.3	31
115	Reduced mRNA expression in paraffin-embedded tissue identifies MLH1- and MSH2-deficient colorectal tumours and potential mutation carriers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 9-16.	2.8	6
116	Immune Response Against Frameshift-Induced Neopeptides in HNPCC Patients and Healthy HNPCC Mutation Carriers. Gastroenterology, 2008, 134, 988-997.	1.3	319
117	An In Vitro System for the Determination of Individualized Immunosuppression. Transplantation Proceedings, 2008, 40, 918-920.	0.6	5
118	Lysates of S. pyogenes Serotype M49 Induce Pancreatic Tumor Growth Delay by Specific and Unspecific Antitumor Immune Responses. Journal of Immunotherapy, 2008, 31, 704-713.	2.4	19
119	Induction of an Antitumoral Immune Response by Wild-Type Adeno-Associated Virus Type 2 in an In Vivo Model of Pancreatic Carcinoma. Pancreas, 2007, 35, 63-72.	1.1	7
120	Expression of an endogenous retroviral sequence from the HERVâ€H group in gastrointestinal cancers. International Journal of Cancer, 2007, 121, 1417-1423.	5.1	49
121	Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer. European Journal of Cancer, 2006, 42, 981-987.	2.8	13
122	Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine, 2006, 24, 2238-2247.	3.8	35
123	Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor. European Journal of Human Genetics, 2006, 14, 561-566.	2.8	53
124	Effective Antitumoral Immune Responses Are Not Induced by Cytosine Deaminase Suicide Gene Transfer in a Syngeneic Rat Pancreatic Carcinoma Model. European Surgical Research, 2006, 38, 513-521.	1.3	4
125	Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-Lymphocyte lines for transfer in patients with renal cell carcinoma. International Journal of Cancer, 2005, 117, 256-264.	5.1	27
126	Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background. Cancer, 2004, 100, 1978-1986.	4.1	7

#	Article	IF	CITATIONS
127	WT1 is a tumor-associated antigen in colon cancer that can be recognized byin vitro stimulated cytotoxic T cells. International Journal of Cancer, 2004, 109, 385-392.	5.1	65
128	The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World Journal of Gastroenterology, 2004, 10, 3583.	3.3	31
129	Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immunity, 2004, 4, 14.	3.2	62
130	Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. Journal of Clinical Immunology, 2003, 23, 415-423.	3.8	56
131	Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2. International Journal of Cancer, 2002, 100, 606-614.	5.1	4
132	Frameshift peptide-derived T-cell epitopes: A source of novel tumor-specific antigens. International Journal of Cancer, 2001, 93, 6-11.	5.1	202
133	Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Therapy, 2000, 7, 1357-1364.	4.6	23
134	In vivo adenovirus mediated gene transfer of the Eschericha coli cytosine meaminase gene to pancreatic tumours induces chemosensitivity to 5-fluorocytosine. Gastroenterology, 2000, 118, A529.	1.3	0
135	Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Therapy, 2000, 7, 1357-1364.	4.6	8
136	Recombinant gp100 protein presented by dendritic cells elicits a T-helper-cell responsein vitro andin vivo. , 1999, 83, 547-554.		13